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Abstract
Background: Corneal cross-linking (CXL) using ultraviolet light-A (UV-A) and riboflavin is a technique developed in
the 1990’s to treat corneal ectatic disorders such as keratoconus. It soon became the new gold standard in multiple
countries around the world to halt the progression of this disorder, with good long-term outcomes in keratometry
reading and visual acuity. The original Dresden treatment protocol was also later on used to stabilize iatrogenic
corneal ectasia appearing after laser-assisted in situ keratomileusis (LASIK) and photorefractive keratectomy (PRK).
CXL efficiently strengthened the cornea but was also shown to kill most of the keratocytes within the corneal
stroma, later on repopulated by those cells.
Review: Ultraviolet-light has long been known for its microbicidal effect, and thus CXL postulated to be able to
sterilize the cornea from infectious pathogens. This cytotoxic effect led to the first clinical trials using CXL to treat
advanced infectious melting corneal keratitis. Patients treated with this technique showed, in the majority of cases,
a stabilization of the melting process and were able to avoid emergent à chaud keratoplasty. Following those
primary favorable results, CXL was used to treat beginning bacterial keratitis as a first-line treatment without any
adjunctive antibiotics with positive results for most patients. In order to distinguish the use of CXL for infectious
keratitis treatment from its use for corneal ectatic disorders, a new term was proposed at the 9th CXL congress in
Dublin to rename its use in infections as photoactivated chromophore for infectious keratitis -corneal collagen
cross-linking (PACK-CXL).
Conclusion: PACK-CXL is now more frequently used to treat infections from various infectious origins. The original
Dresden protocol is still used for this purpose. Careful modifications of this protocol could improve the efficiency of
this technique in specific clinical situations regarding certain types of pathogens.
Keywords: Infectious Keratitis, Corneal cross-linking, Keratoconus, CXL, PACK-CXL, Corneal ulcer, Ultraviolet light A,
Riboflavin
Background
The management of corneal ectatic disorder was com-
pletely transformed this past decade through the devel-
opment and rise of the corneal cross-linking (CXL)
technique in many academic and non-academic clinical
settings around the world. Originally developed in Eur-
ope, more precisely in Germany and Switzerland, CXL
proposed a new therapeutic alternative to patients with
progressive keratoconus with the option of stabilizing
the disease through a one-time extra-ocular surgical
treatment [1, 2]. Easy to perform and efficient after one
treatment, this technique became the benchmark for the
treatment of progressive keratoconus. With this initial
success, the technique was later adapted to treat iatro-
genic corneal ectatic disorders [3, 4], bullous keratopathy
[5, 6], and melting corneal ulcerations [7]. Initially, only
advanced cases of corneal keratitis were treated, but
more recently, beginning infections are also responding
positively to CXL (Fig. 1, a-d). The number of publica-
tions reporting successful treatment of infectious kera-
titis with CXL is increasing. CXL could become a new
alternative to standard treatment of infectious keratitis
in the future.
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CXL for corneal ectasia
CXL was initially developed to treat progressing corneal
ectatic disorders such as keratoconus. The idea is to arti-
ficially strengthen the cornea biomechanically in order
to stop the progression of the disease through the com-
bination of ultraviolet light and a photo-reactant within
the corneal stroma. The method was initially developed
by Theo Seiler, Eberhard Spoerl, and Gregor Wollensak.
Their first report tested this hypothesis ex vivo on
porcine corneas and obtained good results, later con-
firmed in vivo in rabbits and ex vivo on human cor-
neas [2, 8–10]. The first clinical trial was published in
2003 treating 23 eyes with CXL, stabilizing the dis-
ease in all patients [1].
CXL was performed using the combination of ultravio-
let light type A (UV-A) and vitamin B2 (also known as
riboflavin). The original Dresden protocol mentions that
the epithelium is mechanically removed, followed by ap-
plication of a 0.1 % riboflavin solution [11]. Once the
corneal stroma is soaked with riboflavin, UV-A light
(365 nm) is used to irradiate the cornea for 30 min
(3 mW/cm2 irradiance). Riboflavin is a photo-reacting
molecule, which produces free radicals within the cor-
neal stroma when photoactivated. These free radicals
interact with the local collagen and proteoglycan mole-
cules to create new covalent bonds and thus strengthen
the overall biomechanical resistance of the cornea. La-
boratory testing on human corneas reported an increase
in corneal rigidity by an average of 300 % after this
protocol [2]. Some caution was taken when performing
this surgery as only cornea thicker than 400 μm without
the epithelium were treated in order to avoid damage to
the endothelium [11]. Specific protocols have since been
developed to address the issue of thin corneas using a
hypo-osmolaric riboflavin solution [12, 13]. This surgery
has now been proven to be efficient in the long term
with excellent results of disease stabilization over
10 years, and reduces the need of corneal transplant in
this population [13–17]. Further, it not only stops the
progression of the disease in adults and in children [18–
20], but also flattens the keratometry readings in some
[1, 16]. Under certain circumstances, however, even CXL
fails to stabilize the biomechanically weakened cornea,
i.e. in pregnancy [21].
This first accomplishment of halting the progression
of keratoconus using CXL led to another application of
this technology. CXL was used to treat iatrogenic cor-
neal ectatic disorders developed after laser-assisted in
situ keratomileusis (LASIK) and photorefractive keratec-
tomy (PRK) [3, 4]. In clinical trials, CXL stabilized Kmax
values, improved corrected distance visual acuity (CDVA),
and proved to be an efficient treatment for those rare
postoperative complications [3, 4, 22–24].
A new field to explore
Very early in the history of CXL, another field was ex-
plored where the concept of CXL could also be applied. In
2000, Seiler and his team reported the use of CXL for ad-
vanced non-infectious corneal melting [25]. This pilot trial
treated four patients with corneal melting of various non-
infectious origins [25]. The rationale was that an increase
in covalent bonds amongst the collagen molecules might
help stabilize the disease and avoid any à chaud corneal
surgery in these patients. Of four patients, three showed
stabilization of the melting process after CXL, whereas the
last patient continued to progress despite treatment. From
this pilot data, it was concluded that CXL could, in some
cases, stabilize the cornea even though a pathological
process had already modified its structure.
Fig. 1 Pre- and post-treatment peripheral infectious keratitis. a Anterior segment photography of a patient with early peripheral infectious keratitis
(arrow). b Anterior segment OCT of the lesion. c Anterior segment photography of the same patient 7 days after PACK-CXL (9 mW/cm2 irradiance for
10 min) with resolution of the peripheral infectious keratitis (arrow). d Anterior segment OCT of the lesion at day 7 after PACK-CXL
Tabibian et al. Eye and Vision  (2016) 3:11 Page 2 of 5
PACK-CXL for keratitis
The treatment of advance corneal melting came back
into clinical perspective 8 years later with a clinical trial
from Iseli and colleagues where therapy-resistant cases
of melting corneas were treated with CXL. This time,
every case was of infectious origin [7]. In this small co-
hort study, five patients with advanced corneal melt of
infectious origin were selected. Two patients presented a
fungal keratitis, whereas the other three were infected
with Mycobacterium spp. pathogen. Each patient pre-
sented a disease unresponsive to full topical and sys-
temic microbicidal therapy. They received CXL with the
standard Dresden protocol technique: 3 mW/cm2 CXL
for 30 min [2, 7]. After surgery, the melting process was
halted in four out of five patients. The last patient
showed a persistent corneal melt caused by an immune
reaction without any remaining active pathogen. This
study not only confirmed the previous results from Sei-
ler and colleagues from the year 2000, but also intro-
duced the concept that CXL might be efficient when
treating corneal melts from an infectious origin. Subse-
quently, further clinical trials on advanced melting
corneas, one meta-analysis, and multiple animal experi-
ments confirmed those initial results [20, 26–53].
The next step after treating therapy-resistant cases of
advanced infectious keratitis was to treat early cases with
CXL. Thus in 2011, Makdoumi and colleagues from
Sweden proposed a prospective non-randomized clinical
trial to investigate the efficiency of CXL as first line ther-
apy in bacterial keratitis [35]. They recruited 16 patients
clinically diagnosed with infectious bacterial keratitis
who had not received any previous antibiotic (topical or
systemic) treatment. All patients were treated with
standard CXL as mentioned in the Dresden protocol (3
mw/cm2 for 30 min with 0.1 % riboflavin) [1]. Of 16 pa-
tients, 15 showed complete epithelial closure and all
showed signs of improvement and reduction of inflam-
matory response to the bacteria. Nevertheless, two pa-
tients needed additional antibiotic therapy to treat their
disease [35]. The Swedish team uncovered the microbici-
dal effect of CXL in early bacterial keratitis as a first-line
treatment in this trial.
CXL has been shown to be an efficient treatment sta-
bilizing not only advanced melting corneal ulcers, but
also early infectious keratitis of bacterial origin over a
10-year period [26, 37, 41, 44–47, 54]. Photoactivated
chromophore for keratitis-corneal collagen cross-linking
(PACK-CXL) has a very good healing rate regarding bac-
teria (average 88 %) as reported in a recent meta-
analysis and most of the clinical trials are reporting a
successful treatment rate when using PACK-CXL in
combination with standard antimicrobial therapy [55].
Regarding fungal infections, healing rates are also good
(average 78 %). Some of those infections healed with an
additional intervention after PACK-CXL. Healing rate
might be different when using PACK-CXL alone and
further clinical trials are needed to study this issue. Re-
garding acanthamoeba keratitis, 10 out of 11 cases
healed, five of them with retreatment. Although this
meta-analysis reports good healing rates for acanth-
amoeba keratitis, caution should be taken in monitoring
patients as almost half of them needed retreatment [55].
More complicated clinical situations were also addressed
in few reports using PACK-CXL to treat combined
pathological situations with infectious keratitis such as
bullous keratopathy or late-onset infections of a corneal
graft [56, 57].
Riboflavin and ultraviolet light have been used for de-
cades to kill pathogens, in combination or separately
(surface and water disinfection, blood sterilization prior
to transfusion, etc.). Therefore, the microbicidal effect of
CXL can be explained through the effect of these two el-
ements. First, ultraviolet (UV) light itself has a strong
antimicrobial activity as it directly damages DNA and
RNA in microbes such as bacteria, but also viruses, and
inhibits microbes from replicating [58–61]. Riboflavin
also possesses its own microbicidal effect. When it is
photoactivated, it releases reactive oxygen species (ROS)
that directly interact with the nucleic acids and cell
membranes of the microbe [62, 63]. The combined effect
of UV-A light and riboflavin has been shown to be su-
perior than their separate effect, with a 10-fold increased
cytotoxicity when compared to UV-A alone [58, 64].
With the increasing number of publications on CXL
to treat infectious keratitis, a new terminology regarding
this specific use was proposed at the 9th International
Cross-Linking Congress in 2013. It aims to distinguish
CXL for infections from CXL for corneal ectasia in order
to avoid confusion in scientific publications and proto-
cols. The term PACK-CXL: Photo-Activated Chromo-
phore for Keratitis – Corneal Cross-Linking was
adopted for CXL when treating infectious keratitis [31].
Conclusion
CXL was initially developed to stabilize keratoconus.
The Dresden protocol was developed after abundant la-
boratory research including animal trials. This protocol
was tailored to only treat cornea with an ectatic disorder
and to protect the endothelium, avoiding any other com-
plication. As a safe protocol it was used when applying
CXL to other diseases in order to avoid any non-
desirable postoperative effect, and most studies continue
using it for PACK-CXL as originally established. Our
group recently demonstrated that an optimization of the
protocol’s parameters allows reducing the treatment
time without impairing its killing rate on bacterial
strains [43]. Already in the literature, some report suc-
cessful treatment of accelerated protocols in humans
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and animals [50, 65]. PACK-CXL follows the Bunsen-
Roscoe law of reciprocity and accelerated PACK-CXL
could be clinically efficient compared to the standard
Dresden protocol with careful modifications of the
protocol regarding the pathogen type (bacteria, fun-
gus, amoeba) in order to maintain an appropriate kill-
ing rate [50, 65, 66].
PACK-CXL now needs further protocol modifications
to tailor the treatment to a specific pathogen or clinical
situation. Adjustments of treatment parameters such as
irradiation duration, type of chromophore, and fluence
used might help increase the microbicidal efficiency of
PACK-CXL depending on the type of pathogen. With
the possible development of PACK-CXL treating early
keratitis and beginning infiltrates, the need for a more
cost effective method will be necessary. Cheaper, lighter
and smaller devices could support the use of PACK-CXL
for early infectious keratitis and help reduce the burden
of multi-drug-resistant pathogens and patient’s compli-
ance in those clinical situations.
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